FORM PT01390 (REV. 11-2000)

INT OF COMMERCE PATENT, AND TRADEMARK OFFICE

TRANSMITTAL LETTER TO THE UNITED STATES

ATTORNEY'S DOCKET NUMBER 030639.0027.US1

	DESIGNATED/ELECTED	U.S. APPLICATION NO. If known, sec 37 CFR 1.5					
	CONCERNING A FILING	09/889330					
	INTERNATIONAL APPLICATION NO. PCT/US00/00902	INTERNATIONAL FILING DATE 14 January 2000 (14.01.00)	PRIORITY DATE CLAIMED 14 January 1999 (14.01.99)				
	TITLE OF INVENTION NOVEL EXENDIN AGONIST FORMULATIONS AND METHODS OF ADMINISTRATION THEREOF						
	APPLICANT(S) FOR DO/EO/US YOUNG, Andrew; L'ITALIEN, James J.; KOLTERMAN, Orville						
	Applicant herewith submits to the United States Designate/Elected Office (DO/EO/US) the following items and other information:						
	1. A This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.						
	2. This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.						
	3. This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.						
	4.  The US has been elected by the expiration of 19 months from the priority date (Article 31).						
	5. A copy of the International Application as filed (35 U.S.C. 371(c)(2))						
	a.  is attached hereto (required only if not communicated by the International Bureau).						
	b.  has been communicated by the International Bureau.						
	c. 🛛 is not required, as the application was filed in the United States Receiving Office (RO/US).						
	6. An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).						
	b. has been previously submitted under 35 U.S.C. 154(d)(4).						
	7. Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))						
	a.  are attached hereto (required only if not communicated by the International Bureau).						
	b. 🔲 have been communicated by the International Bureau.						
	c ☐have not been made; however, the time limit for making such amendments has NOT expired.						
	d. [have not been made and will not be made.						
	8.  An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3)).						
	9. An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).						
	10. An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).						
	Items 11 to 20 below concern document(s) or information included:						
	11. An Information Disclosure Statement under 37 CFR 1.97 and 1.98.						
	12. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.						
	13. 🖾 A FIRST preliminary amendment.						
	14. A SECOND or SUBSEQUENT preliminary amendment.						
	15. A substitute specification.						
	16. A change of power of attorney and/or address letter.						
	17. A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 - 1.825.						
	18. ☐A second copy of the published international application under 35 U.S.C. 154(d)(4).						
	19. A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).						
	20. Other items or information:						

	U.S. APPLICATION NO. (if known, see 37 C.	INTERNATIONAL APPLIC	ATION NO.	ATTORNEY'S DO	OCKET NUMBER			
	09/889330	PCT/US00/00902		030639.0027.US1				
	21.   The following fees are submitted:			CALCULATIONS PTO USE ONLY				
	BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) – (5)):							
	Neither international preliminary fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a (2)) paid to USPTO and International Search Report not prepare by the EPO or JPO							
	International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO							
	International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO							
dereid	International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(l-4)							
	International preliminary examination fee (and all claims satisfied provisions of PCT Ar							
	ENTER APPROPRIAT	ΓE BASIC FEE AM	IOUNT =	\$ 860.00				
State Species Species Species 2	Surcharge of \$130.00 for furnishing the oath		☐ 20	\$ 130.00				
	from the earliest claimed priority date (37 CI CLAIM S NUMBER FILED	R 1.492(e)).  NUMBER EXTRA	RATE	\$	L			
	Total claims $242 - 20 = 222$	NOMBER EXTRA	x \$18.00	\$ 3,996.00	\$			
[1]	Independent claims 14 - 3 = 11		x \$80.00	\$ 880.00	\$			
	MULTIPLE DEPENDENT CLAIM(S) (if ap	plicable)	+ \$270.00	\$ 270.00	\$			
is up?	TOTAL OF ABOVE CALCULATIONS =			\$ 6,136.00				
ant.	☐ Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above			\$ 3,068.00				
1107	are reduced by 172.			\$ 3,068.00				
	Processing fee of \$130.00 for furnishing the English translation later than 20 30 months			\$ 3,008.00				
1, 4,	from the earliest claimed priority date (37 CFR 1.492(f)).			Δ				
[:]	TOTAL NATIONAL FEE =			\$ 3,068.00				
a=k	Fee for recording the enclosed assignment (37 CFR 1321(h)). The assignment must be			\$				
	accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +			\$ 3,068.00				
	TOTAL FEES ENCLOSED =				6			
				Amount to be refunded:	\$			
				charged:	\$			
	a. \( \text{A check in the amount of \$\frac{\$3,068.00}{}\) to cover the above fees is enclosed.							
	b. Please charge my Deposit Account No in the amount of \$ to cover the above fees. A duplicate copy of this sheet is enclosed.							
Į.	c. A The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>50-1273</u> . A duplicate copy of this sheet is enclosed.							
	d. Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit card in formation should not be included on this form. Provide credit card information and authorization on PTO-2038.							
	NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137 (a) or (b)) must be filed and granted to restore the application to pending status.							
I	SEND ALL CORRESPONDENCE TO:							
		7)//3/0/	>14					
	Bradford J. Duft, Esq. Brobeck, Phleger & Harrison LLP	, , ,	SIGNATURE		-			
J	12390 El Camino Real							
	12390 El Camino Real San Diego, California 92130		Edward O. Kreusser, Esq NAME	·				

09/889330

## JC18 Rec'd PCT/PTO 1 3 JUL 2001

## US NATIONAL APPLICATION

UNDER 35 U.S.C. 371

TITLE: NOVEL EXENDIN AGONIST FORMULATIONS AND METHODS OF

ADMINISTRATION THEREOF

APPLICANT(S): YOUNG, Andrew; L'ITALIEN, James J.; KOLTERMAN, Orville

Correspondence Enclosed:

Transmittal Letter under 35 U.S.C. 371 (2 pgs); Preliminary

Amendment (5pgs); Check in the amount of \$3,068.00; and Return

Postcard

"EXPRESS MAIL" Mailing Label Number <u>EL675945955US</u> Date of Deposit <u>July 13, 2001</u> I hereby certify under 37 CFR §1.10 that this correspondence is being deposited with the United States Postal Service as "Express Mail Post Office to Addressee" with sufficient postage on the date indicated above and is addressed to the Commissioner for Patents, Washington, D.C. 20231.

Edward O Kreusser